Arcadia Biosciences, Inc.

NasdaqCM RKDA

Arcadia Biosciences, Inc. Price to Sales Ratio (P/S) on January 14, 2025: 1.27

Arcadia Biosciences, Inc. Price to Sales Ratio (P/S) is 1.27 on January 14, 2025, a 118.39% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Arcadia Biosciences, Inc. 52-week high Price to Sales Ratio (P/S) is 1.66 on December 10, 2024, which is 30.61% above the current Price to Sales Ratio (P/S).
Arcadia Biosciences, Inc. 52-week low Price to Sales Ratio (P/S) is 0.45 on April 15, 2024, which is -64.61% below the current Price to Sales Ratio (P/S).
Arcadia Biosciences, Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 0.78.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqCM: RKDA

Arcadia Biosciences, Inc.

CEO	Mr. Thomas J. Schaefer C.F.A.
IPO Date	May 15, 2015
Location	United States
Headquarters	202 Cousteau Place
Employees	21
Sector	Consumer Staples
Industries Agriculture Biotechnology

Description

Arcadia Biosciences, Inc. produces and markets plant-based health and wellness products in the United States. It engages in developing crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients, health and wellness products, and their viability for industrial applications. The company was incorporated in 2002 and is headquartered in Davis, California.

Key trends

Past 5 years